The record confirms when the last injection actually occurred
The Core Benefits of Microdosing Liver and Cardiovascular Protection A 72-week trial found 40% of patients achieved resolution of fatty liver disease without worsening fibrosis. In animal models, GLP-1s suppress fat production in the liver and reduce inflammation. Tirzepatide at low doses showed particularly strong cardiovascular benefits, with meaningful improvements across multiple lipid markers linked to heart disease risk. Cholesterol storage forms increased far less with tirzepatide, and harmful lipids like ceramides showed minimal increase compared to placebo
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications used primarily for type 2 diabetes management and, in some formulations, for chronic weight management
3.6 Sensitivity analysis Sensitivity analysis was conducted by sequentially excluding individual studies and re-running the combined analysis for AST, ALT, SOD, MDA, and GSH
The enzymes sulfatase, 3-hydroxysteroid dehydrogenase, aromatase, and 17-hydroxysteroid dehydrogenase (type 1 and type 2) are some of the enzymes of interest for several researchers since they participate in the metabolism of steroid hormones, such as the biosynthesis of estrogen and progesterone [118,119]
